Apr 23, 2020
2020 Market Spotlight: Sjogren's Syndrome
Apr 21, 2020
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Apr 21, 2020
IMBRUVICA® (ibrutinib) Receives 11th FDA Approval
Dec 07, 2019
IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
Dec 07, 2019
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Oct 09, 2019
Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Aug 05, 2019
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Jul 23, 2019
Insights Into the Global Polyacrylamide Market 2019-2024: Growth, Trends, Opportunities, Forecasts, Players - ResearchAndMarkets.com
Jul 12, 2019
Imbruvica (ibrutinib; AbbVie/Johnson & Johnson) Drug Overview & Product Profiles 2017-2026
Jun 07, 2019
Global Polyacrylamide Market Size, Share & Trends Analysis Report 2019-2025: Anionic, Cationic, Non-ionic - ResearchAndMarkets.com
May 29, 2019
The global polyacrylamide market size is expected to reach USD 6.8 billion by 2025, expanding at a CAGR of 6.2% over the forecast period
Mar 21, 2019
Global Acrylamide Market - Growth, Trends and Forecasts (2019-2024) - ResearchAndMarkets.com
Feb 14, 2019
Ascentage Pharma Appoints Jeff Kmetz as Chief Business Officer
Jan 28, 2019
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Dec 03, 2018
IMBRUVICA® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sep 28, 2018
Global & Chinese Iso-Butoxy Methacrylamide (CAS 16669-59-3) Industry: 2018 Market Research Report - ResearchAndMarkets.com
Jun 01, 2018
IMBRUVICA® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström's Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin's Lymphoma
Apr 26, 2018
Super Absorbent Polymers: Global Market Forecasts to 2023: Drivers, Restraints and Opportunities - ResearchAndMarkets.com
Dec 11, 2017
IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition
Dec 05, 2017
IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint